These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24773344)

  • 1. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
    Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
    Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance.
    Nomura M; Ishii H; Kawakami A; Yoshida M
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1030-8. PubMed ID: 19654286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet.
    Ushio M; Nishio Y; Sekine O; Nagai Y; Maeno Y; Ugi S; Yoshizaki T; Morino K; Kume S; Kashiwagi A; Maegawa H
    Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E293-304. PubMed ID: 23715726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
    Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
    FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
    Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LXR driven induction of HDL-cholesterol is independent of intestinal cholesterol absorption and ABCA1 protein expression.
    Kannisto K; Gåfvels M; Jiang ZY; Slätis K; Hu X; Jorns C; Steffensen KR; Eggertsen G
    Lipids; 2014 Jan; 49(1):71-83. PubMed ID: 24163219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
    Yoshida M
    Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
    Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
    Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
    Ahmed MH; Byrne CD
    Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
    Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yasuda O; Ogawa H; Kim-Mitsuyama S
    J Pharmacol Exp Ther; 2010 Oct; 335(1):70-5. PubMed ID: 20651026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet.
    Toyoda Y; Takada T; Yamanashi Y; Suzuki H
    Lipids Health Dis; 2019 Dec; 18(1):234. PubMed ID: 31883528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.
    Wang X; Ren Q; Wu T; Guo Y; Liang Y; Liu S
    Mol Med Rep; 2014 Dec; 10(6):2917-23. PubMed ID: 25310357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
    Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
    World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
    Van Rooyen DM; Gan LT; Yeh MM; Haigh WG; Larter CZ; Ioannou G; Teoh NC; Farrell GC
    J Hepatol; 2013 Jul; 59(1):144-52. PubMed ID: 23500152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats.
    Chang E; Kim L; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park CY
    World J Gastroenterol; 2015 Jul; 21(25):7754-63. PubMed ID: 26167075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.
    Jia L; Betters JL; Yu L
    Annu Rev Physiol; 2011; 73():239-59. PubMed ID: 20809793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear receptors and cholesterol metabolism in the intestine.
    Moschetta A
    Atheroscler Suppl; 2015 Feb; 17():9-11. PubMed ID: 25659870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver.
    Tang W; Jia L; Ma Y; Xie P; Haywood J; Dawson PA; Li J; Yu L
    Biochim Biophys Acta; 2011 Sep; 1811(9):549-55. PubMed ID: 21683156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.